Beclometasone/formoterol
Подписчиков: 0, рейтинг: 0
| Combination of | |
|---|---|
| Beclometasone dipropionate | Glucocorticoid |
| Formoterol fumarate | Long-acting β2 agonist |
| Clinical data | |
| Trade names | Fostair |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
Beclometasone/formoterol, sold under the brand name Fostair, is an inhalable fixed-dose combination drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains beclometasone dipropionate and formoterol fumarate dihydrate. It is inhaled.
It was approved for medical use in the United Kingdom in 2007, and in Australia in February 2020. It is on the World Health Organization's List of Essential Medicines.
External links
- "Beclometasone dipropionate". Drug Information Portal. U.S. National Library of Medicine.
- "Formoterol fumarate". Drug Information Portal. U.S. National Library of Medicine.
| Glucocorticoids |
|
||||
|---|---|---|---|---|---|
| Antiglucocorticoids |
|
||||
| Synthesis modifiers | |||||
| |||||